chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Lost consciousness for approximately 2 seconds immediately following vaccination. BP was 64/36, pulse 51, and O2 was 99%. By 1140 am BP was 82/60. Patient recovered and was able to walk out of facility without assist.
Heart is fluttering, I am having a fast Heartbeat; I got my first dose vaccine, it was painful; I had a slight fever from 99.7 then it went down to 99.4 and now it is still 99.2; I have been very tired and  I started feeling more exhausted; I am having a fast Heartbeat; This is a spontaneous report from a contactable consumer or other non healthcare professional (patient). A patient of unspecified age and gender received bnt162b2 (BNT162B2, Formulation: solution for injection, Lot Number: EY0584), dose 1 via an unspecified route of administration on 01Aug2021 as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient reported that my heart was fluttering, I was having a fast heartbeat, I got my first dose vaccine, it was painful, I had a slight fever from 99.7 then it went down to 99.4 and now it was still 99.2, I had been very tired and  I started feeling more exhausted, I am having a fast heartbeat. Consumer stated that, I got my first dose of Pfizer vaccine on 01Aug2021 (this past sunday) and it was painful but very normal but it went away but I have been very tired since then. This afternoon I am running a fever, I had a slight fever from 99.7 then it went down to 99.4 and now it is still 99.2 and I have been really tired. This was just my first shot of the Pfizer vaccine I mean 4 days ago. Is this was something that I need to be concerned. I had been experiencing my heart is fluttering, my hear flutters. I was having a fast heartbeat and I had been very tired since then. The events outcome was unknown.  Follow-ups attempts completed.  No further information is expected.
chills, fever over 102, terrible headache, body aches, sore arm, loss of appetite, nausea, severe fatigue, congestion
My husband had tested positive for COVID-19 and two days later I tested positive as well. I took a COVID-19 Home Test and then it was really two days before I started having symptoms. I really only had a runny nose and bad brain fog. It was really hard to think for about a week. In February I did get a viral infection and I did need to get an inhaler and had a really hard time breathing. I have not tested positive for COVID-19 again, but I concerned that having COVID-19 has weakened my lungs as I have never had breathing issues like this when sick before and it has hit me really hard.
Migrain on day 1 &2 after vaccine; Lightheaded and slight dizziness on day 1; Drowsiness on Day 1 after; This is a spontaneous report from contactable Other Health Professional, the patient.  A 53-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number unknown), via an unspecified route of administration on 16Feb2021 at 12:45 (at the age of 53-years-old) as a single dose in the left arm for COVID-19 vaccination. Medical history was reported as "none." The patient has no allergies. Historical vaccinations include the first dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number unknown) on 28Jan2021 at 09:00 in the right arm. The vaccine was administered to the patient at a workplace clinic. The patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were reported as "none." The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient reported that she experienced a migraine beginning at 3:30 AM on 17Feb2021 (reported as "on Day 1 and 2 after vaccine")  Additionally, she experienced being lightheaded and having slight dizziness and drowsiness beginning at 3:30 AM on 17Feb2021 (reported as "on Day 1"). The patient did not receive any treatment for the events. The clinical outcomes of the events migraine, dizziness and drowsiness were reported as recovered (date not specified). It was also reported that since the vaccination, the patient had not been tested for COVID-19.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Shortness of breath, cyanotic, irritability, fever over 39.5 ° C, on the verge of convulsions, paleness.
A nurse reported the occurrence of injection site redness in a 16 month old male who was vaccinated with Infanrix for prophylaxis. There was no relevant medical history, concurrent conditions, or concurrent medication. The subject had no adverse experiences following receipt of prior immunizations. On an unspecified date, the vaccinee received an injection of Infanrix (528E9); the number of previous injections of Infanrix was not reported. One day post-immunization, the vaccinee developed an area of redness at the injection site measuring 10cm by 7cm. The vaccinee was seen by the physician, who prescribed Zyrtec. This event resolved after "several days."
This case was reported by a consumer and described the occurrence of influenza-like symptoms in a patient who received SHINGRIX for prophylaxis. In September 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced influenza-like symptoms and generalized rash. On an unknown date, the outcome of the influenza-like symptoms and generalized rash were recovered/resolved. It was unknown if the reporter considered the influenza-like symptoms and generalized rash to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received SHINGRIX, 5 month before reporting date and experienced flu like symptoms for almost a week followed by a rash all over body. The patient was wondering if he did not get the booster, does the one shot still provide any immunity.
Woke up in the middle of the night with a cluster headache that lasted several hours. Then the following afternoon after being active for a couple hours, got very dizzy with chills and nausea, needed to lie down for several hours (suspected vasovagal syncope/sudden drop in blood pressure, which did not respond immediately to Midodrine).
Approx 2-3 hours after receiving the COVID vaccine, developed facial flushing, red rash on chest wall.  denied respiratory, cardiovascular or gastro-intestinal disorders.  Took 50 mg benadryl and Instructed to go to ED, spoke with the PA who confirmed only cutaneous symptoms. Checked CBC with diff and serum tryptase. Prescribed prednisone 40 mg.  Temporary modest improvement of skin symptoms, but upon returning home increased flushing on face, chest wall, as well as posterior rhinorrhea.  Instructed to continue prednisone 20 mg BID, famotidine 20 mg BID
Site: Pain at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: arm swelling and soreness-Severe
Symptoms - woke up from sleep with tingling hands and feet, felt paralyzed (heavy hands and feet), breathing affected - felt paralyzed, but still able to breathe Treatment - considered whether to go to hospital emergency department, but symptoms resolved by morning
Had a headache in the evening, but ithad passed in the morning.; lack of sleep; This is a spontaneous report from a non-contactable pharmacist. An elderly male patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on 14Mar2021 as a single dose for COVID-19 immunisation. It was unknown if the patient had any relevant medical history. It was unknown if the patient had any known allergies. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown if the patient received any other vaccines within four weeks prior to the vaccination. It was unknown if the patient received any concomitant medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation. On 14Mar2021, the patient experienced headache in the evening, but it had passed in the morning. He also mentioned that it could be also been from lack of sleep on an unknown date in 2021. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the event headache was recovered on an unknown date in 2021, while the event lack of sleep was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I Positive for COVID-19 on 22MAR2023, I have a sore throat I have an blister feeling on my mouth and I feel supper tired. I am exposed everyday, I started taking paxlovid yesterday and I feel okay so far. My fever is up just a little bit not too much.
8 x 5 cm erythema and warmth. Denies dyspnea no swelling noted. No systemic symptoms noted. Advised to ice site and take BENADRYL and go to ER for difficulty breathing. VS WNL.
Throat is very itchy; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Er8735) via an unspecified route of administration in the left arm on 20May2021 at 16:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included gastroesophageal reflux disease (GERD) and blood pressure high on an unknown date and unknown if ongoing. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN); atorvastatin (MANUFACTURER UNKNOWN) and omeprazole (PRILOSEC) all for an unknown indication from an unknown date and unknown if ongoing. The patient was not allergic to medications, food, or other products. The patient also received unspecified nasal drip as concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0161) via an unspecified route of administration in the left arm on 29Apr2021 at 09:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21May2021 at 18:00, the patient experienced very itchy throat. The patient reported that the event was perhaps from nasal drip or allergy reaction due to the shot. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event very itchy throat was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
30 minutes post vaccination: Patient began feeling nausea and began shaking. Assisted to exam table, assisted to lay down, assisted to elevate legs. Complained of mid-sternal pain. Applied cold compresses to forehead. BP and pulse taken (BP 150 & systolic; carotid 64 & regular). Skin warm and dry. Color pink. Patient did not complain of respiratory distress. Observed patient another 15 minutes. Patient reported less chest discomfort. Breathing improved but shaking persisted. Decision made to call EMTs. BP and pulse taken again (BP 160 systolic & palpated and carotid pulse 68 & regular). Upon EMT arrival, patient appeared to have full body seizure. Turned to side, supported head, ensured airway open. Transported via ambulance to hospital.
Patient complained of itching at injection site. Chest tightness, itching in her throat & eyes at 45 minutes after injection. I checked BP which was 200/100. Called 911 EMS came & evaluated patient & determined she was not having an anaphylactic reaction but offered to take her to the emergency department but she declined. They advised her to take diphenhydramine which we provided for her.
Developed rhinitis & fevers to 103 within 24 hrs. of receiving intranasal H1N1 vaccine.
About 24 hrs after vaccine I had chills with NO fever. Strong headache which I could feel going down my neck into my back between my shoulder blades. I just had this all over "I feel awful feeling." Took Ibuprofen 800mg about 3 hours later. Went to bed and woke up in the middle of the night feeling better. Felt just tired the next day until about 2pm and a slight headache until about 4pm.
stomach cramps; confusion; fatigued; little headache; difficulty breathing; vision issues; cloudy and fogginess; vomiting; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of   in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     The patient's past medical history included Lupus syndrome and COPD. Concomitant products included SALBUTAMOL SULFATE (INHALERIN), ALPRAZOLAM (XANAX), LISINOPRIL and EZETIMIBE (ZETIA) for an unknown indication.   On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient was treated with ONDANSETRON (ZOFRAN [ONDANSETRON]) ongoing since an unknown date at an unspecified dose and frequency; OXYGEN ongoing since an unknown date at an unspecified dose and frequency and MORPHINE ongoing since an unknown date at an unspecified dose and frequency.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.
Noticed this am-site red and size of penny, felt like a bruise/hard, removed sweater this afternoon-site was bigger, reddened, warm to touch, painful with palpation. Reported to clinic-oral temp 99.1 and c/o H/A since yesterday, but has H/A frequently with weather change. Site marked.
This case was reported by a healthcare professional and described the occurrence of lightheadedness in a female subject aged between 20 and 29 years old who was vaccinated with ENGERIX B (GlaxoSmithKline). On the morning of 20 October 2010 the subject received unspecified dose of ENGERIX B (20 mcg, unknown route, unknown arm). On the morning of 20 October 2010, less than one day after vaccination with ENGERIX B, the subject experienced lightheadedness. The subject attended the Emergency Room, but was not hospitalized. On 20 October 2010, the event was resolved. The healthcare professional considered the event was probably related to vaccination with ENGERIX B. The healthcare professional reported that 3 subjects had experienced lightheadedness after vaccination with ENGERIX B. This is case 2 of 3 (see case IDs A0888918A and A0888946A for the other reports). Follow-up information was received on 10 November 2010 via physician who reported the 39-year old subject's immunization series with ENGERIX B was discontinued. At the time of the report no other information was provided. The lot number was reported as AHBV855AA from the reporter; however, based on a safety lot number review, the lot number was updated to AHBVB855AA.
A nurse who was assisting with vial dilution, erroneously took a one dose vial that had recently been transported from a mobile team and diluted the vial, thinking it was an unconstituded vial.  This resulted in one client receiving an under-dose vaccine.  Another nurse immediately removed the vial and communicated this information to MPOD Manager.  Once alerted,  a supervisor was immediately contacted so she could advise further.  The conclusion was that the client (DOB:  03/15/75), received an under-dose vaccine and would need to be vaccinated with a full dose, on the opposite arm, per CDC guidelines.
death  (non-ST elevated myocardial infarction)  (acute kidney injury)
Information has been received from a consumer concerning a daughter of a friend who on an unspecified date was vaccinated with Gardasil (Lot# not provided).  The consumer reported that her "friends daughter had the Gardasil vaccine and had a near death experience".  It was not reported if the patient sought medical attention for the event.  No further information is available.
Patient states that even months (4 months) after the vaccine it has a burning sensation without touching it and it itches occasionally
swelling in the lymph nodes; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (swelling in the lymph nodes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LYMPHADENOPATHY (swelling in the lymph nodes). At the time of the report, LYMPHADENOPATHY (swelling in the lymph nodes) outcome was unknown.            No concomitant medications reported by investigator  No treatment medications provided by the reporter.
upper-left chest / heart pain. lasted for an hour. eased as soon as I lay down.  (plus headache, muscle pain in the legs, fever during the first and the second night (101.5F))
Patient came to clinic for the first vaccine of Pfizer on 01/25/21. Patient came back for 2nd dose too early on 02/06/21 and received the 2nd dose in series of Pfizer.
Information has been received from a physician concerning a 14 year old female with no relevant medical history and no drug allergy who on 29-JUL-2008 was vaccinated with the first dose of GARDASIL vaccine (yeast) (dose, route and site of administration and lot number not reported). There was no illness at the time of vaccination. The second suspect therapy included varicella virus vaccine live (lot number not reported). Other concomitant therapy included meningococcal ACYW conj vaccine (dip toxoid) (MENACTRA) and hepatitis A vaccine (inactive) (HAVRIX). The patient developed dizziness and nausea while getting into the car to leave the physician's office. The patient sought medical attention and was taken back into the office to observe. Subsequently the symptoms resolved. The patient recovered from dizziness and nausea and was as discharged home. Additional information has been requested.
Some dizziness. Started an hour after vaccine. Around 7:45 am, April 12th, I experienced some disorientation. Felt disconnected from reality, and as a result I felt highly anxious and paranoid. I drank water; I didn't have access to medication since I was at work. My job is auditing paperwork, and I frequently lost track of what I was doing and wasn't even sure where I was. I went to the bathroom at one point, and I kept sitting at my desk questioning whether I was even at my desk and not still in the bathroom. I became so anxious that around 8:30 am, I talked to my boss and she told me that I could go home if I felt I needed to. I finished my task and around 9:10 am, I left work and went home. I still feel strange and am scared that I won't feel any better tomorrow.
Information has been received from a medical assistant concerning an infant who on 01-JUN-2009 was vaccinated with PNEUMOVAX 23 (0.5ml, SQ) instead of PREVNAR in error. No adverse effect was reported. It was unknown if the patient sought medical attention. Follow-up information has been received from a nurse who stated that she was unable to determine the patient's name or date of birth. The reporter stated that the vaccination error was a human error which resulted when the employee who was not familiar with vaccines for infants pulled up the wrong pneumococcal vaccine. The patient did not have any AE's as a result. No further information is available.
Administration of expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine) in an 81-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 059H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 31-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The vial was initially stored in the refrigerator on 17 Mar 2022. The vials did not undergo any temperature excursion.  No treatment medications were reported.   This case was linked to MOD-2022-531825 (Patient Link).
Developed large red area  (5?x8?) on arm at injection site.  Included slight swelling, but no pain or itching present. Noticed small area 11 days after vaccinated , which increased in size daily until redness started to subside on day 15. Begin taking oral Benadryl on day 14.
Emergency room with symptoms of cough, fever, phlegm and sinus congestion since 4/14.  He had an outpatient COVID test positive on 4/16.  His fevers reoccurred so his PCP obtained a CXR showing atypical pnuemonia, started him on azithromcyin and solumedrol on 4/22.  He presents today with worsening shortness of breath, now hypoxic on day 9 of his infection.  He got the Johnson & Johnson vaccine on 4/7.
This is a spontaneous report from a contactable nurse via a Pfizer Company representative. This nurse reported similar events for two patients. This is the first of two reports. Only this case is serious. A 52 year-old female patient of an unspecified race/ethnicity received PREVNAR 13 via an unspecified route of administration in the arm on an unspecified date at 0.5 ml single for immunisation. The patient medical history and concomitant medications were not reported.  The patient experienced local cellulitis (red and tender like at the area where she got the shot). The nurse reported that when the doctor reviewed the patient there were not swollen lymph nodes or soreness or anything like that, it was just this tender to touch the part, the patient was able to move her arm and hand without any problems. The doctor gave to the patient cephalexin (KEFLEX) 500 mg four times a day for 5 days and 6 tablets of prednisone 20 mg, then 1 tablet of prednisone twice a day for 3 days. Outcome of the event was unknown. Event was considered related to pneumococcal 13-val conj vac (dipht crm197 protein).; Sender's Comments: The reported event vaccination site cellulitis is possibly related to PREVNAR 13. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators as appropriate.
Day after vaccine started with mild sick symptoms. Recovered rather quickly. Since then, has had severe abdominal pain, chest pain, anxiety, depression, and migraines. Has been seen in the ER three times, has had to see family doctor multiple times. Was seen by cardiology, psychiatry, and gastroenterology. Has had multiple chest x-rays, EKGs, MRI, and is scheduled for endoscopy.